IL-1β dysregulates cGMP signaling in the newborn lung

Area of Science:

• Pulmonary Medicine
• Molecular Biology
• Cell Signaling

Background:

• Cyclic guanosine monophosphate (cGMP) signaling is crucial for newborn lung function and development.
• Decreased cGMP signaling is observed in newborn lung injury, but underlying mechanisms remain unclear.

Purpose of the Study:

• To investigate how Interleukin-1 beta (IL-1β) regulates the expression of the α1-subunit of soluble guanylate cyclase (sGCα1), a key component of pulmonary cGMP signaling.

Main Methods:

• Utilized human fetal lung fibroblast cell lines (IMR-90) and primary mouse pup lung fibroblasts.
• Assessed sGCα1 mRNA and protein levels following IL-1β treatment.
• Investigated the roles of Transforming growth factor-β (TGFβ)-activated kinase-1 (TAK1) and Nuclear factor-κB (NF-κB) signaling pathways.
• Employed chromatin immunoprecipitation and transgenic mouse models.

Main Results:

• IL-1β treatment rapidly decreased sGCα1 mRNA and protein expression at the transcriptional level.
• TAK1 signaling was essential for IL-1β-mediated sGCα1 downregulation.
• NF-κB signaling, specifically RelA binding to the sGCα1 promoter, was critical for this regulation.
• In vivo studies confirmed IL-1β induces TAK1 and reduces sGCα1 protein in newborn lungs.

Conclusions:

• IL-1β inhibits pulmonary cGMP signaling by transcriptionally suppressing sGCα1 expression.
• The IL-1β-TAK1-NF-κB axis is a key mechanism controlling sGCα1 levels in the newborn lung.
• Understanding this pathway offers insights into newborn lung injury and potential therapeutic targets.